V

Viatris

D
VTRS
USD
-0.18
(-1.374%)
Market Closed
381,338.00
Volume
2.69
EPS
4.16
Div Yield
-23.925926
P/E
15,420,284,381.96
Market Cap
Today
-1.3740%
1 Week
11.188%
1 Month
13.632%
6 Months
15.719%
12 Months
40.282%
Year To Date
18.969%
All Time
0%

Title:
Viatris

Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Do you need help or have a question?